News

Press Releases

Celsius in the News

August 3, 2023

Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease
February 27, 2023

Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO – Inflammatory Bowel Diseases
January 19, 2023

Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
September 22, 2022

Celsius Therapeutics Names Scientific Advisers
August 25, 2022

Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
March 24, 2022

Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022

December 1, 2022

Best Places to Work 2022

Boston Globe
September 6, 2022

PharmaVOICE 100 Innovators: Jeanne Magram

PHARMAVOICE
September 1, 2022

Machine learning powers biobank-driven drug discovery

NATURE BIOTECHNOLOGY
March 24, 2022

Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic

MEDCITY NEWS
March 24, 2022

Celsius aims to cool down inflammation with new investors and more pharma deals

ENDPOINTS
May 3, 2021

Single-Cell Analysis Comes of Age, Lighting the Way for Precision Therapies

TIMMERMAN REPORT
December 21, 2020

Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics

ENDPOINTS
August 13, 2020

Digital Health 150 of 2020

CB INSIGHTS
August 1, 2020

PharmaVOICE 100 Commander & Chiefs: Tariq Kassum

PHARMAVOICE
May 11, 2020

Active machine learning helps drug hunters tackle biology

NATURE BIOTECHNOLOGY